Critical Pharmacodynamic Warning
brigatinib affects the metabolic pathway.
When patients take brigatinib concurrently with drugs metabolized by , the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.
Clinical Overview for brigatinib
This page outlines known interaction pathways involving brigatinib, focusing primarily on its profile as a affecting the pathway.
Enzyme Interaction Profile
brigatinib demonstrates potency against . Clinical significance of this interaction requires further evaluation.
Inhibitor
A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.
Clinical Example: brigatinib affectsInducer
A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.
Interaction Details
| Drug Name | brigatinib |
| Affected Enzyme | |
| Inhibitor Strength | Unknown |
| Inducers | No inducers listed |
| Inhibitors | No inhibitors listed |
Clinical Recommendations
Consult primary literature for guidance.
- Therapeutic drug levels
- Adverse effect monitoring
- Clinical response assessment
- Consider dose reduction
- Evaluate alternative therapies
- Adjust based on response
Quick Facts
14017
Enzyme Inhibition
Unknown
Clinical Significance
Clinical significance requires further evaluation.
Information Sources
- FDA Drug Interaction Database
- Clinical Pharmacology Guidelines
- Pharmaceutical Labeling Information
- Published Clinical Studies
Last updated: July 30, 2026